Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.
JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial
![JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial]()
Reviewed by jenisht
on
December 05, 2018
Rating:
No comments: